Skip to main content


Corporate Finance

Mirabaud bietet ein breites Spektrum an Finanz- und Beratungsdienstleistungen für Unternehmen an, die unseren Kunden bei der Erreichung ihrer strategischen Ziele unterstützen sollen. Mirabaud, das im Herzen der Märkte aktiv ist, bietet institutionellen Anlegern zudem unabhängiges und ideenbasiertes Research zu Nischensegmenten des Aktienmarkts, zusammen mit hochmodernen Ausführungsdienstleistungen.



Case Study


Mirabaud acted as the Company's exclusive advisor in the structuring, execution and completion of the fundraising process of CHF 6M for the Series A funding of Scailyte.

About Scailyte

  • Scailyte, a Swiss company founded in 2017 as an ETH Zürich spin-off and based in Basel at the Novartis Campus (Switzerland) and in Cambridge-MA (USA), aims at advancing precision medicine with single-cell technologies, artificial intelligence, and multi-omics analysis.
  • The company has developed a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data and is composed of the two business units:
    • ScaiVision –providing services and establishing co-development projects – and
    • ScaiDx –developing proprietary biomarkers.
  • Scailyte has developed biomarker signatures in diverse therapeutic areas with high level of accuracy and has the potential to span from discovery to translation into clinics and diagnostics.

Transaction overview

  • The scope of the project was to support the Scailyte’s fundraising process and help it secure the completion of the CHF 6M Series A round of financing with new resources to allow the Company to accelerate the achievement of its development and commercial milestones.
  • The Series A funding was coordinated by Mirabaud by collaborating with a Swiss family office, previous investors including Swiss-based institutional investors and an established Mirabaud bank vehicle.
  • Scailyte’s priorities will be focused on:
    • progressing their biomarkers, with the United States as the primary target market;
    • building strategic partnerships in single-cell omics, cell & gene therapy, and translational oncology to increase the success rate of clinical trials for novel anti-cancer therapies;
    • expanding the discovery capabilities of its best-in-class single-cell analytics platform.

Mirabaud contribution and added value

  • Mirabaud acted as the Company's exclusive advisor in the structuring, execution and completion of the fundraising process for the Series A funding of Scailyte.
  • Mirabaud managed:
    • structuring the T&Cs of the financing,
    • preparation of the project information and coordination of the Due Diligence,
    • elaboration of the Business Plan,
    • estimation of the future value creation pathways;
    • review of the legal documentation for the closing of the transaction.
  • Mirabaud acted as the hub for the transaction by merging a differentiated and international community of investors in a very concrete and time-efficient manner towards a mutual objective.

Key data


Scailyte AG

Industry vertical

Digital Healthcare


Capital growth


CHF 6'000’000

Mirabaud’s role

Exclusive Advisor


Case Study

Case Leader

Wählen Sie Ihre Sprache